Biography

Dr. Sean Cao was appointed as our Chief Business Development Officer in September 2025 and has served as a Director of I-Mab since May 2025. Dr. Cao currently serves as Operating Partner of CBC Group (formerly C-Bridge Capital), a position he has held since January 2024. Dr. Cao co-founded ABio-X Holdings in May 2021 and serves as the company’s Chief Executive Officer. Dr. Cao also co-founded and served as the first Chief Executive Officer of Ensem Therapeutics from May 2021 to June 2023. In addition, Dr. Cao co-founded and currently serves on the board of directors of RVAC Medicines and Jadeite Medicines. In 2017, Dr. Cao co-founded Everest Medicines and served as its Chief Executive Officer until 2020. While building Everest Medicines, Dr. Cao also incubated NiKang Therapeutics with its scientific co-founders in the United States, where he served as the Chief Executive Officer from its inception until 2020, and the chairman of its board of directors until September 2021. Dr. Cao also served as the Chief Business Officer for I-Mab Biopharma from the company’s inception in 2016 until 2018. Prior to his tenure as Chief Business Officer of I-Mab Biopharma, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group (“Simcere”). Dr. Cao was also the President and director at Simcere of America, a wholly owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi. Before Sanofi, Dr. Cao was an associate at New Leaf Venture Partners. Dr. Cao worked in the pharmaceutical and diagnostic industries for several years before joining New Leaf Venture Partners, first at Aventis, then at Johnson & Johnson. Dr. Cao received a Ph.D. in Microbiology from the University of Virginia, an MBA with honors from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.